Metered Dose Inhaler Devices Market Report 2025

This Metered Dose Inhaler Devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The metered dose inhaler devices market size has grown strongly in recent years. It will grow from $15.46 billion in 2024 to $16.36 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historical period can be attributed to the rising prevalence of diabetes, a higher demand for metered dose inhaler devices, an increase in the number of metered dose inhaler devices, and a growing incidence of chronic obstructive pulmonary disease (COPD).

The metered dose inhaler devices market size is expected to see strong growth in the next few years. It will grow to $20.29 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be driven by the growing prevalence of chronic obstructive pulmonary diseases (COPD), the rising incidence of asthma, an increase in infectious diseases, a higher rate of diabetes, and a rise in respiratory diseases. Key trends expected in the forecast period include technological advancements, the development of innovative therapies, regulatory approvals, the introduction of new inhalers, and the widespread use of online marketing tools.

The growing prevalence of chronic obstructive pulmonary diseases (COPD) is expected to drive the expansion of the metered dose inhaler (MDI) devices market. COPD is a progressive lung condition marked by airflow restriction, usually caused by prolonged exposure to irritants such as cigarette smoke, and leads to symptoms such as shortness of breath, coughing, and wheezing. The rise in COPD cases can be attributed to factors such as tobacco consumption, air pollution, an aging population, and delayed diagnosis or treatment. MDI devices are vital in managing COPD by delivering medication directly to the lungs, offering rapid relief and improving airflow. For example, in December 2023, the National Institutes of Health, a US-based government agency, projected that COPD cases would increase from 532 million in 2030 to 592 million by 2050. Consequently, the growing prevalence of COPD is fueling the demand for metered dose inhaler devices.

Leading companies in the metered dose inhaler devices market are concentrating on developing advanced technologies, such as pressurized metered dose inhalers (pMDIs), to boost medication delivery efficiency and increase patient adherence. pMDIs are devices that release a specific dose of medication in aerosol form using a pressurized propellant. For example, in July 2023, Lupin Limited, an India-based pharmaceutical company, introduced Luforbec 100/6, a pMDI aimed at treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This inhaler combines 100 µg of beclometasone and 6 µg of formoterol, offering an effective combination therapy for patients. Notably, Luforbec is priced around 47% below the fixed reference price, making it more affordable. Given that approximately 5% of adults in Germany suffer from asthma, this launch highlights Lupin's dedication to meeting significant healthcare demands and improving respiratory care outcomes.

In March 2022, R-V Industries, Inc., a US-based manufacturer of industrial equipment, acquired MBC Aerosol Inc. for an undisclosed sum. This acquisition is intended to strengthen R-V Industries' aerosol processing and packaging capabilities, broaden its operations beyond Pennsylvania, and support its growth strategy through acquisitions, ensuring greater stability and efficiency across multiple industries. MBC Aerosol Inc. is a US-based manufacturer specializing in the production of metered dose inhalers (MDIs).

Major players in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, and Iconovo AB.

North America was the largest region in the metered dose inhaler devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metered dose inhaler devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metered dose inhaler devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metered dose inhalers (MDIs) are medical devices that deliver a specific amount of aerosolized medication directly into the lungs through inhalation. These inhalers are widely used to manage respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and various other lung diseases.

There are several types of metered dose inhaler devices, including desktop metered dose inhalers, portable metered dose inhalers, and others. Desktop metered dose inhalers are fixed devices primarily found in clinical environments, providing a controlled dose of aerosolized medication. These devices are available through both online and offline distribution channels and are commonly used for conditions such as asthma and COPD. They serve a range of end users, including hospitals, clinics, homecare settings, and more.

The metered dose inhaler devices market research report is one of a series of new reports that provides metered dose inhaler devices market statistics, including metered dose inhaler devices industry global market size, regional shares, competitors with a metered dose inhaler devices market share, detailed metered dose inhaler devices market segments, market trends and opportunities, and any further data you may need to thrive in the metered dose inhaler devices industry. This metered dose inhaler devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metered dose inhaler devices market consists of sales of products including bronchodilators, corticosteroids, combination inhalers, and anticholinergics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.